Skip to Content
  • For public
    • What is a medicine?
      • Generic substitution
      • Generic products
        • Frequently asked questions
    • What is a biosimilar?
      • Frequently asked questions about biological drugs and biosimilars
    • What is a food supplement?
    • Safety of medicines
      • Monitoring the safety of medicinal products
      • Adverse reactions
      • Submitting a report on an adverse reaction
      • Medicinal products under additional monitoring
      • Product defects
      • Drug interactions
      • Pharmaceutical injuries
    • Correct use of medicines
      • Ensure the safety of your medication
      • Instructions for the safe use of medicines
      • Monitor the effects of your medication
      • How to store medicines?
      • How should medicines be disposed of?
    • List of medicines
    • Where can I find reliable information about medicines?
      • How can I assess the reliability of drug information?
      • Medicinal product packs
      • Package leaflet
    • How are medicines supplied to users in Finland?
      • What factors affect the availability of medicines?
      • Why might a pharmacy run out of my medicine?
      • Obligatory storing of medicines
      • Exemptions and special permits
    • Ordering medicines online
      • Why is the food supplement I ordered considered to be a medicine?
    • Medicines for children
      • Developing better medicines for children
      • Collaboration on medicines education
    • Medication of the elderly
    • What medicines can I bring abroad?
    • Pain relievers and self-care
    • Bringing medicines to Finland
      • Fimea’s services to citizens
        • Cooperation with patient associations
    • Influenza
      • Influenza vaccinations
      • Antiviral medication
      • Pandemic
    • Vaccines
    • Falsified medicines
    • Medicines and pregnancy
    • Pharmaceuticals and the environment
    • Antimicrobial resistance
    • Medicines that have marketing authorisation in Finland
  • Current events
    • Substitution of biological medicines
      • Information for medicine users
      • Information for health care professionals
    • Fimea and wellbeing services counties
    • Coronavirus (COVID-19)
      • Frequently asked questions (COVID-19)
      • Adverse reactions reported on corona vaccines
    • Russian attack on Ukraine
    • News archive
    • Subscribe newsletter
  • Databases and registers
    • FimeaWeb
    • Meds75+
      • Frequently asked questions
    • National High-Risk Medicines Classification
      • Frequently asked questions
    • Consumption
    • Self-medication products
    • Basic register
      • Plasma-derived products with marketing authorisation
    • Substitutable medicinal products
      • Textfile for databases
      • Criteria used in compiling the list
    • ATC codes
    • Shortages
  • Development and HTA
    • Assessment of pharmacotherapies (HTA)
      • Assessment of hospital-only medicinal products
      • Topic selection
      • Nordic collaboration through JNHB
      • Assessment reports (in Finnish)
    • Development of medicines information
      • National Medicines Information Network
      • Materials of the Medicines Information Network
    • Medication Therapy Indicators
      • Use of Avoidable Medications in the Elderly
      • Significant Polypharmacy in the Elderly
      • Drug Expenses for the Elderly
    • Patient advisory board
    • Research
      • Research Network for Rational Pharmacotherapy (RATTI)
  • Marketing authorisations
    • Marketing authorisation application
      • Finland as a Reference Member State in the decentralised procedure (DCP)
      • Finland as a Reference Member State in the Mutual Recognition / Repeat Use Procedure (MRP/RUP)
      • Changing of Reference Member State duties to Finland
      • Finland as a rapporteur in the centralised marketing authorisation procedure (CP)
      • Granted and cancelled marketing authorisations
      • Pending marketing authorisation applications
      • Biological Medicinal Products
      • Orphan drugs
      • Paediatric medicines
      • European Pharmacopoeia
      • Active substance names and standard terms
    • Product Information
      • Summary of product characteristics
      • Package leaflet
      • Package labelling
      • Text templates
      • Braille and package leaflets for the visually impaired
      • Trade names of medicinal products
      • Strength
      • Translating influenza vaccines in Finland
    • Electronic marketing authorisation submissions
      • What's new
      • Instructions for electronic marketing authorisation submissions
      • Special characteristics of the electronic marketing authorisation process for veterinary medicines
    • Introduction to market
    • Shortage notifications
      • Frequently asked questions about reporting shortages
    • Innovation Office
      • Informal Regulatory Guidance
      • Scientific Advice
      • SNSA advice
    • Safety features
    • Other permits
      • Exemption
    • Interchangeable medicinal products
    • Herbal remedies and medicinal products
      • Herbal medicinal products
      • Traditional herbal medicinal products
      • Homeopathic and anthroposophic preparations
    • Parallel import
    • Cancelling a marketing authorisation or registration and sunset clause
      • Cancelling a marketing authorisation or registration
      • Expiration of marketing authorisations and registrations (sunset clause)
      • Sunset clause - concepts
      • Sunset clause exemption
      • List of expired marketing authorisations and registrations
    • Renewals and variation applications
      • Renewals
      • Variation applications
      • Changes to labelling
      • Transferring a marketing authorisation to a new holder
      • Article 5 classification requests for variation applications
      • OTC application
    • Frequently asked questions about marketing authorisations
  • Medical devices
    • What are medical devices?
      • Definition of medical devices
      • Special device groups
        • Software
        • Biomaterials
        • Nanomaterials
      • How to identify a medical device?
    • Topical information about devices
      • Fees for medical devices
    • Notifications and applications
      • Certificate of free sale
      • Derogation
    • Incident reports
    • Device and operator registrations
      • Device and operator notifications to Eudamed
      • Device and operator notifications to CERE
      • Details of registered operators
    • Legislation related to medical devices
    • Device manufacturers
      • Intended purpose and classification
      • General safety and performance requirements
      • Clinical evaluation and clinical investigations
      • Conformity assessment
      • CE marking
      • Labelling and instructions for use
      • Post-market surveillance
        • System and plan
        • Reports to be prepared
      • Manufacturer's incident reporting procedure
        • Incident report
          • IMDRF codes
    • Device distributors and importers
      • Importers
      • Distributors
        • Distributors' obligations
        • National language requirements
        • Reporting of incidents
        • Import to Finland of at-home tests
      • Repackaging and making of translations
    • Products without a medical purpose
    • Investigations with devices
      • Clinical investigations of devices
      • Performance studies of IVD-devices
      • Medical Device Advisory Clinic
    • Notified bodies
      • Designation of notified bodies
      • Supervision of notified bodies
      • Devices subject to specific additional procedures
    • Marketing of medical devices
  • Pharmaceutical safety and information
    • Pharmaceutical safety
      • Reporting adverse reactions
        • Frequently asked questions about reporting adverse drug reactions (ADRs)
    • Biological medicinal products
      • Advanced Therapy Medicinal Products
    • Biosimilars
      • Biosimilars in Finland
      • The position of Fimea towards interchangeability of biosimilars
    • Regulation on Medicinal Products for Paediatric Use
      • Paediatric Committee
      • Paediatric Investigation Plan
      • Coordination and communication
      • Rewards and incentives
      • Symbol in the labels of medicinal products
  • Pharmacies
    • Pharmacy licences
      • How to apply for a pharmacy licence
      • How to apply for a subsidiary pharmacy licence
      • Supervision Committee
      • Change of pharmacist situations
    • Pharmacy tax
    • Special permits
      • Applying for a special permit – Information for prescribers
      • Applying for a special permit – Information for the releasing party
      • Decision on the special permit, processing times and fees
      • Fixed-term special permits
      • Frequently Asked Questions
    • Manufacturing medicinal products
    • Schengen certificates
    • PIC/S GMP Guide
    • Dose-dispensing
  • Supervision
    • Pharmacovigilance
      • Adverse reaction reporting (EudraVigilance)
      • Pharmacovigilance inspections
      • Product defects
      • Summaries of risk management plans
      • Product-specific risk minimisation material
      • Pharmacovigilance requirements for parallel distribution and parallel import products
    • Clinical Drug Trials
      • Clinical Trials Regulation & CTIS
      • Trials under the EU Regulation
        • Trial application and modifications
      • Transition of clinical trials
      • Safety reporting in clinical trials
      • GCP inspections
      • Frequently asked questions about Clinical drug trials
    • Advertising of medicinal products
    • Classification
      • Principles of classification
      • Classification application
      • List of medicines
      • After classification
    • Pharmaceutical industry
      • Licenses
        • Local pharmaceutical wholesale license holders
      • Registered brokers of medicinal products
    • Good Laboratory Practice (GLP)
    • Obligatory storing of medicines
      • List of products to be stocked as obligatory storage
      • Notifying the obligatory storages
      • Applying for a permit to maintain lower obligatory storage levels
      • Applying for an exemption
      • Special arrangements for the fulfilment of storage obligation
    • Establishments
      • Supervising tissue establishments
      • Supervision of organ activity
    • Certificates of a Pharmaceutical Product (CPP)
      • Applying for an export certificate
    • Narcotics control
      • Additional information to be submitted with narcotics licence applications
      • Frequently asked questions
    • Batch-specific control
    • GMP certificates
    • Gene technology
      • Supervision of contained use
        • Inspection process
      • Supervision of deliberate release
      • Gene technology register
    • Laboratory of Fimea
      • National and international collaboration
    • Legislation, regulations and guidelines
      • European Pharmacopoeia
        • National pharmacopoeia documents
        • To users of the Pharmacopoeia
        • CEP Procedure
        • International Non-proprietary Names for Pharmaceutical Substances (INN)
        • Additional Pharmacopoeia materials
      • Administrative regulations and guidelines
    • Blood services
      • Licence of a Blood Establishment
      • Hospital Blood Banks
      • Hemovigilance
      • Blood as a starting material for medicines
      • Legislation on blood service activities
    • Biobanks
      • Biobank consent
      • National biobank register
      • Guidance and supervision of biobanks at Fimea
    • Tissue establishments
      • Licence for tissue establishment
      • Tissue establishment register
      • Biovigilance
      • Regulations on human tissues and cells
      • Instructions for tissue establishments
  • Veterinary
    • Marketing authorisation procedures
      • National procedure
      • Mutual recognition procedure
      • Decentralised procedure
      • Centralised procedure
      • Validity of marketing authorisations
      • Applications for variations to marketing authorisations for veterinary medicines
    • Special permits for compassionate use
      • Applying for special permit
      • FAQ
        • A Questions and answers on how to fill in the form
        • B Questions and answers regarding the technical aspects of permit application
        • C Questions and answers regarding the decision and the processing of the application
        • D Other questions and answers
      • List of special permits for veterinary medicinal products
    • Adverse effects
    • Consumption of veterinary antimicrobials
      • The European Surveillance of Veterinary Antimicrobial Consumption ESVAC
    • Clinical trials on veterinary medicinal products
      • Immunological products
    • Withdrawal period and MRL
      • What is a withdrawal period?
      • MRL
      • Horses as food-producing animals
    • Private import
  • About us
    • Contact us
      • Change of address
      • Copyright
      • Contact
      • Personnel
      • Secure Mail
    • Open positions
    • Forms
    • Organisation
      • Strategy
      • Sustainability
      • International representation
        • International and EU cooperation
      • Fimea committees
    • Publications
    • Fees
      • Frequently asked questions about invoicing
    • Estimated processing times
    • Data requests
    • Data access authorisations
    • Open data
    • Reports of breaches in accordance with the act on whistleblower protection
    • Frequently asked questions
  • Annual report 2023
  • Annual report 2022
  • Annual report 2021
  • Annual report 2020
    • Fimea's Year 2020
    • Economy 2020
    • Statistics 2020
    • Pharmaceutical information 2020
    • Responsibility 2020
    • Fimea in brief 2020
  • Valitse kieli Suomi
  • Välj språket Svenska
  • Select language English

  • Management review

  • Fimea is strongly involved in the management of the corona epidemic

  • Travel restrictions speeded up the adoption of remote inspections

  • Fimea's new strategy

    Sustainable wellbeing through safe medicines and medicinal products, combined with effective service.

  • Accessible to all

    Fimea has made a lot of effort to ensure accessibility.

Fimea, Lääkealan turvallisuus- ja kehittämiskeskus

P.O. Box 55, 00034 FIMEA FI

029 522 3341

[email protected]

© Fimea 2023

Fimea promotes the health and safety of the population by regulating medicinal, medical devices, blood and tissue products, biobanks and by developing the pharmaceuticals sector.

Information about this website

  • Data protection (in Finnish)
  • Cookie policies
  • Accessibility statement